A Study Evaluating KTE-X19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)



Status:Recruiting
Conditions:Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/2/2019
Start Date:March 7, 2016
End Date:March 2034
Contact:Medical Information
Email:medinfo@kitepharma.com
Phone:1-844-454-5483(1-844-454-KITE)

Use our guide to learn which trials are right for you!

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)

The primary objectives of this study are to determine the safety and efficacy of KTE-X19
adult participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia
(ALL).


Key Inclusion Criteria:

1. Relapsed or refractory B-precursor ALL defined as one of the following:

- Primary refractory disease

- First relapse if first remission ≤ 12 months

- Relapsed or refractory disease after 2 or more lines of systemic therapy

- Relapsed or refractory disease after allogeneic transplant provided individuals
is at least 100 days from stem cell transplant at the time of enrollment

2. Morphological disease in the bone marrow (≥ 5% blasts)

3. Individuals with Ph+ disease are eligible if they are intolerant to tyrosine kinase
inhibitor (TKI) therapy, or if they have relapsed/refractory disease despite treatment
with at least 2 different TKIs

4. Age 18 or older

5. Eastern cooperative oncology group (ECOG) performance status of 0 or 1

6. Adequate renal, hepatic, pulmonary and cardiac function defined as:

- Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 cc/min

- Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 2.5 x
upper limit of normal (ULN)

- Total bilirubin ≤ 1.5 mg/dl, except in individuals with Gilbert's syndrome.

- Cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion, and no
clinically significant arrhythmias

- Baseline oxygen saturation > 92% on room air

7. In individuals previously treated with blinatumomab, CD19 tumor expression in bone
marrow or peripheral blood.

Key Exclusion Criteria:

1. Diagnosis of Burkitt's leukemia/lymphoma according to World Health Organization (WHO)
classification or chronic myelogenous leukemia lymphoid blast crisis

2. History of malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g.
cervix, bladder, breast) unless disease free for at least 3 years

3. Isolated extramedullary disease

4. Central nervous system (CNS) abnormalities

- Presence of CNS-3 disease or CNS-2 disease with neurological changes

- History or presence of any CNS disorder such as a seizure disorder,
cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any
autoimmune disease with CNS involvement

5. History of concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome,
Shwachman-Diamond syndrome or any other known bone marrow failure syndrome

6. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or
other clinically significant cardiac disease within 12 months of enrollment

7. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of
enrollment.

8. Primary immunodeficiency

9. Known infection with HIV, hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV
positive).

10. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or
requiring IV antimicrobials for management.

11. Prior medication:

- Salvage chemotherapy including TKIs for Ph+ ALL within 1 week prior to enrollment

- Prior CD19 directed therapy other than blinatumomab

- Treatment with alemtuzumab within 6 months prior to leukapheresis, or treatment
with clofarabine or cladribine within 3 months prior to leukapheresis

- Donor lymphocyte infusion (DLI) within 28 days prior to enrollment

- Any drug used for graft-versus-host disease (GVHD) within 4 weeks prior to
enrollment

- At least 3 half-lives must have elapsed from any prior systemic
inhibitory/stimulatory immune checkpoint molecule therapy prior to enrollment

- Corticosteroid therapy for 7 days prior to enrollment

12. Presence of any indwelling line or drain (e.g., percutaneous nephrostomy tube,
indwelling Foley catheter, biliary drain, or pleural/peritoneal/pericardial catheter).
Ommaya reservoirs and dedicated central venous access catheters such as a Port-a-Cath
or Hickman catheter are permitted

13. Acute GVHD grade II-IV by Glucksberg criteria or severity B-D by IBMTR index; acute or
chronic GVHD requiring systemic treatment within 4 weeks prior to enrollment

14. Live vaccine ≤ 4 weeks prior to enrollment

15. Women of child-bearing potential who are pregnant or breastfeeding because of the
potentially dangerous effects of the preparative chemotherapy on the fetus or infant.
Females who have undergone surgical sterilization or who have been postmenopausal for
at least 2 years are not considered to be of childbearing potential

16. Individuals of both genders of child-bearing potential who are not willing to practice
birth control from the time of consent through 6 months after the completion of
KTE-X19

17. In the investigators judgment, the individuals is unlikely to complete all
protocol-required study visits or procedures, including follow-up visits, or comply
with the study requirements for participation

18. History of autoimmune disease (e.g. Crohns, rheumatoid arthritis, systemic lupus)
resulting in end organ injury or requiring systemic immunosuppression/systemic disease
modifying agents within the last 2 years

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
We found this trial at
23
sites
1032 West Sheridan Road
Chicago, Illinois 60153
Principal Investigator: Patrick Stiff, MD
Phone: 708-327-3095
?
mi
from
Chicago, IL
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
Phone: 773-702-9440
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2220 Pierce Ave
Nashville, Tennessee 37232
615-936-8422
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
22 S Greene St
Baltimore, Maryland 21201
(410) 328-8667
Phone: 410-328-8199
University of Maryland Medical Center Founded in 1823 as the Baltimore Infirmary, the University of...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
3855 Health Sciences Dr,
La Jolla, California 92093
(858) 822-6100
Phone: 858-822-6843
UC San Diego Moores Cancer Center Established in 1978, UC San Diego Moores Cancer Center...
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Los Angeles, California 90095
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Nashville, Tennessee 37203
Phone: 615-329-7254
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New York, New York 10029
Phone: 212-241-1598
?
mi
from
New York, NY
Click here to add this to my saved trials
601 Elmwood Avenue
New York, New York 14642
?
mi
from
New York, NY
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: JaeHong Park, MD
Phone: 646-888-1370
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
101 The City Drive South
Orange, California 92868
714-456-7890
University of California, Irvine Medical Center We are UC Irvine Health. We are a devoted...
?
mi
from
Orange, CA
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Sacramento, California 95817
Phone: 916-734-1093
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Armin Ghobadi, MD
Phone: 314-747-2740
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Francisco, California 94143
Phone: 415-476-4765
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Seattle, Washington 98104
Phone: 206-215-1471
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Seattle, Washington 98109
Principal Investigator: Ryan Cassaday, MD
Phone: 206-667-3608
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Tampa, Florida 33612
Phone: 813-745-6939
?
mi
from
Tampa, FL
Click here to add this to my saved trials
101 College Street
Toronto, Ontario M5G 1L7
Principal Investigator: Andre Schuh, MD
Phone: 416 946 4501
?
mi
from
Toronto,
Click here to add this to my saved trials